Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10092236 | 0.92 | TSHR (0.57) | TSHRALDH1A1RECQLGAAEPHX2 | |
| SCHEMBL18997736 | 0.86 | TSHR (0.50) | TSHRALDH1A1RECQLGAAEPHX2 | |
| SCHEMBL2697702 | 0.79 | ALDH1A1 (0.42) | TSHRALDH1A1GAAPOLBSMN1; SMN2 | |
| SCHEMBL13630894 | 0.78 | TSHR (0.50) | TSHRALDH1A1RECQLGAAEPHX2 | |
| SCHEMBL13630898 | 0.78 | TSHR (0.50) | TSHRALDH1A1RECQLGAAEPHX2 | |
| SCHEMBL4881440 | 0.78 | TSHR (0.50) | TSHRALDH1A1RECQLGAAEPHX2 | |
| SCHEMBL13630904 | 0.78 | TSHR (0.46) | TSHRALDH1A1RECQLGAAEPHX2 | |
| SCHEMBL13630895 | 0.76 | TSHR (0.52) | TSHRALDH1A1RECQLGAAEPHX2 | |
| SCHEMBL11382562 | 0.74 | TSHR (0.65) | TSHRALDH1A1RECQLGAAEPHX2 | |
| SCHEMBL16521081 | 0.74 | POLB (0.46) | TSHRALDH1A1GAAPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | YAP1, TERF2IP, TEAD1 | TSHR 2042/4885ALDH1A1 3813/4885RECQL 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.